#4733
Anonymous

    We too are required to have these survivorship care plans in place. Unfortunately the timeline for doing these is a little bit tight and we are definitely missing people. I think long term follow up for patients who have gotten IO therapy both in the adjuvant setting and for those with long term responses in the metastatic setting is going to be crucial. I think we are going to potentially see more long term rheumatologic conditions as well.

    I agree with the comments regarding stage IV patients above. This is a very unique population now in that we are managing more and more patients like a chronic disease, with long term survivors.

    Latest Activity